Search Results - "AGOSTARA, B."

Gemcitabine and vinorelbine in pretreated advanced breast cancer: A pilot study by Valenza, R., Leonardi, V., Gebbia, V., Agostara, B.

“…Purpose: Gemcitabine (GEM) and vinorelbine (VNR) are both active against advanced breast cancer (ABC), being able to induce a median ORR of 25% and 40%,…”
Get full text

Androgen Receptor Status in Nontumoral and Malignant Human Colorectal Tissues by CASTAGNETTA, L., TRAINA, A., CAMPISI, I., CALABRÒ, M., MARATTA, A., SAETTA, A., AGOSTARA, B., MEZZATESTA, N.

“…: Data on androgen receptor (AR) status of nontumoral and malignant human colorectal tissues are compared using ligand binding assay in 22 patients who…”
Get full text

New approaches to breast cancer: oxaliplatin combined with 5-fluorouracil and folinic acid in pretreated advanced breast cancer patients: preliminary reports by Leonardi, V, Savio, G, Laudani, A, Blasi, L, Agostara, B

“…Oxaliplatin is a platinum compound that inhibits DNA synthesis. This drug has a broad spectrum of antineoplastic activity, and its results in breast cancer are…”
Get full text

Ligand Binding and Cytochemical Analysis of Estrogen and Progesterone Receptors in Relation to Follow-Up in Patients with Breast Cancer by CASTAGNETTA, L., TRAINA, A., AGOSTARA, B., MIELE, M., CAMPISI, I., CALABRÒ, M., MARASÀ, L., CARRUBA, G.

“…: Soluble and nuclear estrogen receptor (ER) content was measured by ligand binding assay, and estrogen and progesterone receptors by immunohistochemical…”
Get full text

Folfiri versus xeliri in untreated advanced colorectal cancer: A phase II randomised trial of the Gruppo Oncologico dell’ Italia Meridionale (prot. GOIM 2405) by Giuliani, F, De Vita, F, Maiello, E, Nugnes, I, Di Bisceglie, M, Romito, S, Lorusso, V, Catalano, G, Agostara, B, Colucci, G

Get full text

3546 POSTER (XELOX)Capecitabine plus Oxaliplatin: clinical efficacy and safety in first-line treatment for metastatic gastric cancer by Alu', M, Laudani, A, Leonardi, V, Palmisano, V, Savio, G, Pepe, A, Arcuri, C, Cusimano, M.P, Calabria, C, Agostara, B

Get full text

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial by Palmeri, S., Leonardi, V., Gebbia, V., De Bella, M.Tamburo, Ferraù, F., Faillú, G., Spatafora, M., Valenza, R., Di Vita, G., Vitello, S., Carroccio, R., Sciortino, G., Vaglica, M., Accurso, V., Agostara, B., Licata, G.

“…A phase II study in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) was carried out to evaluate the clinical activity and toxicity of the…”
Get full text

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale by COLUCCI, Giuseppe, GEBBIA, Vittorio, BORSELLINO, Nicola, MISINO, Andrea, ROMITO, Sante, DURINI, Ernesto, CORDIO, Stefano, DI SERI, Marisa, LOPEZ, Massimo, MAIELLO, Evaristo, PAOLETTI, Giancarlo, GIULIANI, Francesco, CARUSO, Michele, GEBBIA, Nicola, CARTENI, Giacomo, AGOSTARA, Biagio, PEZZELLA, Giuseppe, MANZIONE, Luigi

“…We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU…”
Get full text

Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer by Palmeri, S, Leonardi, V, Tamburo De Bella, M, Morabito, A, Vaglica, M, Accurso, V, Ferraù, F, Failla, G, Agostara, B, Massidda, B, Valenza, R, Fanelli, M, Gasparini, G

“…We conducted a multi-institutional phase II study to evaluate the tolerability and activity of a sequential schedule of treatment with doxorubicin and…”
Get more information

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial by Gebbia, V, Mantovani, G, Agostara, B, Contu, A, Farris, A, Colucci, G, Cognetti, F, Restivo, G, Speciale, R, Ferrero, B

“…Vinorelbine has been demonstrated to be active against squamous cell carcinomas of the head/neck (SCHNC) and lung. This multicenter phase II trial was carried…”
Get more information

Recent postmenopause, but not ER status, identifies a subset of primary breast cancer patients with a higher risk of relapse by Traina, A, Liquori, M, Cusimano, R, Calabria, C, Agostara, B, Castagnetta, L

Get more information

Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM) by COLUCCI, G, ROMITO, S, PALAZZO, S, GEBBIA, N, GEBBIA, V, PACILIO, G, GIOTTA, F, TESTA, A, PEZZELLA, G, DURINI, E, AGOSTARA, B, CARIELLO, S

“…Sixty-four consecutive patients with locally advanced (n = 7) or metastatic breast cancer (n = 57), were treated with a combination of laevofolinic acid 100 mg…”
Get full text

Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy by Veronesi, U., Orecchia, R., Zurrida, S., Galimberti, V., Luini, A., Veronesi, P., Gatti, G., D'Aiuto, G., Cataliotti, L., Paolucci, R., Piccolo, P., Massaioli, N., Sismondi, P., Rulli, A., Lo Sardo, F., Recalcati, A., Terribile, D., Acerbi, A., Rotmensz, N., Maisonneuve, P.

“…Background: The need to dissect axillary nodes in patients with early breast cancer and clinically negative axilla remains controversial. The aim of the study…”
Get full text

Is an antiemetic prophylactic treatment needed for patients submitted to consecutive days of 5-fluorouracil? An observational study by De Angelis, Verena, Roila, Fausto, Tonato, Maurizio, Ballatori, Enzo, Del Favero, Albano

“…The necessity of an antiemetic prophylaxis in patients treated with chemotherapy of low emetogenic potential, such as 5-fluorouracil +/- folinic acid…”
Get full text

traditional Mediterranean diet decreases endogenous estrogens in healthy postmenopausal women by Carruba, G, Granata, O.M, Pala, V, Campisi, I, Agostara, B, Cusimano, R, Ravazzolo, B, Traina, A

“…Breast cancer incidence and mortality rates are markedly lower in the south than in the north of Europe. This has been ascribed to differences in lifestyle…”
Get full text

Pain Management in Eight Italian Oncological Care Centres by Barni, S., Borgonovo, K.F., Di Costanzo, F., Cognetti, F., Bernardo, G., Boni, C., Agostara, B., Pronzato, P., Colucci, G., Mammucari, M.

Get full text

Italian Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group Trials. GROCTA Trials by Boccardo, F, Rubagotti, A, Amoroso, D, Mesiti, M, Pacini, P, Gallo, L, Sismondi, P, Giai, M, Genta, F, Mustacchi, G, Agostara, B, Bolognesi, A, Villa, E, Schieppati, G, Ausili Cefaro, G P, Bellantone, R, Farris, A, Sassi, M, Patrone, F

“…The first GROCTA trial compared 5-year tamoxifen treatment to ten chemotherapy cycles in a group of 504 pre-/post-menopausal, node-positive, ER-positive breast…”
Get more information

Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma by Agostara, B, Gebbia, V, Testa, A, Cusimano, M P, Gebbia, N, Callari, A M

“…Patients with metastatic breast carcinoma resistant to first line chemotherapy may require further treatment. Results o second line chemotherapy are still…”
Get more information

Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC): Regional Southern Italy experience by Adamo, V., Ricciardi, G. R. R., Adamo, B., Agostara, B., Caruso, M., Gebbia, V., Gebbia, N., Lavenia, G., Banna, G. L., Mafodda, A., Rossello, R., Butera, A., Spada, S., Borsellino, N., Mangiameli, A., Campiglio, M., Tuccari, G.

“…Abstract only…”
Get full text

Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer by Boccardo, F., Rubagotti, A., Guglielmini, P., Sismondi, P., Farris, A., Amadori, D., Agostara, B., Gambi, A., Catalano, G., Faedi, M.

“…Abstract only e11521 Background: > 3 N+ pts have a poor outcome, even in the presence of otherwise favourable phenotypic features. CT, alone or combined with…”
Get full text